Breaking News

Trials & Filings in Brief: Nov. 21, 2013

By Gil Roth | November 21, 2013

Forest Labs, Gedeon Richter, GSK, Lundbeck, Nanotherapeutics, Otsuka, Pfizer,

Phase I
Pfizer, GSK study combo for melanoma . . . read more

Forest, Richter Schizophrenia Drug Gets CRL . . . read more

Nanotherapeutics meets with FDA over vax-facility . . . read more

Otsuka, Lundbeck monthly Abilify approved in Europe . . . read more

blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • The Western API Industry

    The Western API Industry

    Dr. Enrico T. Polastro, Arthur D. Little||January 28, 2016
    Temporary reprieve or lasting recovery?

  • CMOs: A Flexibility Alternative

    CMOs: A Flexibility Alternative

    Philip K. Burns, CRO-Consulting||January 28, 2016
    A look at how to include CMOs as an option to improve overall flexibility